BioLineRx Ltd. (Nasdaq: BLRX) announced that it has signed an exclusive, worldwide agreement with Yissum Research Development Company of the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments

Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q3 ResultsNovember 22, 2016 2:39 PM BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical CompanyNovember 21, 2016 7:00 AM